AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 301 min read$RAPP

HEALY JAMES purchased $20.4M of RAPP (indirect holdings)

HEALY JAMES purchased 969,480 indirectly-held shares of Rapport Therapeutics, Inc. (RAPP) at $21.00 ($20.36M total) across 4 trades on 2026-10-28.

Original reporting
SEC EDGAR · HEALY JAMES
Published Oct 30, 2026, 11:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bullish
medium confidence
Mentioned
$RAPP
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBullishLow
01

Why it matters

The filing provides fresh, material information about insider confidence, which can influence short‑term price dynamics.

02

Market read

Direct insider buying of a micro‑cap biotech is a notable catalyst that can affect the stock's short‑term trajectory.

03

What to watch

The purchase was made via an open‑market transaction, not a private placement, and may reflect personal portfolio rebalancing rather than company fundamentals.

Relevance 8/10Novelty 7/10Timing: today

Background

SEC Form 4 filing discloses a director's open‑market purchase of Rapport Therapeutics shares.

Company-level read

Ticker impact

$RAPPBullishMedium confidence
Context

Director Healy James bought 969,480 shares of Rapport Therapeutics for $20.4M, increasing his stake to 25,267 shares.

Expected impact

likely upward pressure as the market prices in insider buying

Evidence & confidence

A $20M purchase by a board member is material for a micro‑cap biotech and may trigger short covering or buying interest.

Market effects

Sector

May lift sentiment in the biotech sector as insider confidence is viewed favorably.

Regional

Limited to U.S. markets where the stock trades.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Insider buying could be a signal of upcoming negative news that the director wants to pre‑emptively offset.

Key entities

  • person
    Healy James

    Director of Rapport Therapeutics who made the purchase.

  • company
    Rapport Therapeutics, Inc.

    Biotech firm (ticker RAPP) subject of the insider transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

OCT 30
$RAPPHighAI 9/10

Rapport Therapeutics, Inc. (RAPP): Results of Operations and Financial Condition

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants On October 28, 2026, Rapport Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan

SEC EDGAR 8-K2 min
OCT 28
$RAPPHighAI 9/10

Why is Rapport Therapeutics stock sliding today?

Rapport Therapeutics Inc (RAPP) shares fell 17.1% to $22.84 after pricing a $365 million capital raise, including a $175 million common stock offering at a 24% discount. The company aims to use proceeds for clinical trials and operations through 2029. Insider selling and the large offering size contributed to the decline, with the stock reaching a 52-week low. The broader market was positive, indicating company-specific pressure.

investing.com2 min